nodes	percent_of_prediction	percent_of_DWPC	metapath
Nimodipine—CYP3A4—Imiquimod—skin cancer	0.108	0.256	CbGbCtD
Nimodipine—CYP3A4—Temozolomide—skin cancer	0.108	0.256	CbGbCtD
Nimodipine—CYP3A4—Vismodegib—skin cancer	0.0748	0.177	CbGbCtD
Nimodipine—CACNA1S—pes—skin cancer	0.0666	0.347	CbGeAlD
Nimodipine—CYP3A4—Vemurafenib—skin cancer	0.0591	0.14	CbGbCtD
Nimodipine—CYP3A5—Docetaxel—skin cancer	0.052	0.123	CbGbCtD
Nimodipine—CYP3A4—Docetaxel—skin cancer	0.0203	0.0481	CbGbCtD
Nimodipine—CACNA1D—ear—skin cancer	0.0154	0.0802	CbGeAlD
Nimodipine—NR3C2—Preimplantation Embryo—PADI6—skin cancer	0.0132	0.148	CbGpPWpGaD
Nimodipine—CACNB4—nipple—skin cancer	0.0122	0.0637	CbGeAlD
Nimodipine—Phosphatase alkaline increased—Vismodegib—skin cancer	0.00983	0.033	CcSEcCtD
Nimodipine—CACNB3—nipple—skin cancer	0.00936	0.0488	CbGeAlD
Nimodipine—Platelet count decreased—Imiquimod—skin cancer	0.0087	0.0292	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Vismodegib—skin cancer	0.0082	0.0276	CcSEcCtD
Nimodipine—CACNA1F—head—skin cancer	0.00776	0.0405	CbGeAlD
Nimodipine—Hyponatraemia—Vismodegib—skin cancer	0.00716	0.0241	CcSEcCtD
Nimodipine—AHR—nipple—skin cancer	0.00693	0.0361	CbGeAlD
Nimodipine—Disseminated intravascular coagulation—Docetaxel—skin cancer	0.00578	0.0194	CcSEcCtD
Nimodipine—CACNB3—mammalian vulva—skin cancer	0.00546	0.0285	CbGeAlD
Nimodipine—AHR—Adipogenesis—ASIP—skin cancer	0.00544	0.0612	CbGpPWpGaD
Nimodipine—CACNB4—head—skin cancer	0.0051	0.0266	CbGeAlD
Nimodipine—Deep vein thrombosis—Temozolomide—skin cancer	0.0051	0.0171	CcSEcCtD
Nimodipine—Gastrointestinal symptom NOS—Fluorouracil—skin cancer	0.00486	0.0163	CcSEcCtD
Nimodipine—CACNB3—female reproductive system—skin cancer	0.00468	0.0244	CbGeAlD
Nimodipine—NR3C2—nipple—skin cancer	0.00462	0.0241	CbGeAlD
Nimodipine—NR3C2—Preimplantation Embryo—NKX2-1—skin cancer	0.00435	0.0489	CbGpPWpGaD
Nimodipine—Muscle spasms—Vismodegib—skin cancer	0.00413	0.0139	CcSEcCtD
Nimodipine—CACNB1—head—skin cancer	0.00408	0.0213	CbGeAlD
Nimodipine—AHR—mammalian vulva—skin cancer	0.00405	0.0211	CbGeAlD
Nimodipine—CACNB3—head—skin cancer	0.00391	0.0204	CbGeAlD
Nimodipine—Myalgia—Vismodegib—skin cancer	0.00366	0.0123	CcSEcCtD
Nimodipine—CACNA1C—connective tissue—skin cancer	0.0036	0.0188	CbGeAlD
Nimodipine—Wheezing—Bleomycin—skin cancer	0.00357	0.012	CcSEcCtD
Nimodipine—AHR—female reproductive system—skin cancer	0.00347	0.0181	CbGeAlD
Nimodipine—Nervous system disorder—Vismodegib—skin cancer	0.00344	0.0116	CcSEcCtD
Nimodipine—Deep vein thrombosis—Docetaxel—skin cancer	0.00339	0.0114	CcSEcCtD
Nimodipine—AHR—Adipogenesis—PLIN2—skin cancer	0.0033	0.0371	CbGpPWpGaD
Nimodipine—NR3C2—connective tissue—skin cancer	0.00327	0.0171	CbGeAlD
Nimodipine—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00319	0.0107	CcSEcCtD
Nimodipine—Sweating increased—Imiquimod—skin cancer	0.00316	0.0106	CcSEcCtD
Nimodipine—Phosphatase alkaline increased—Temozolomide—skin cancer	0.0031	0.0104	CcSEcCtD
Nimodipine—Phlebitis—Bleomycin—skin cancer	0.0031	0.0104	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Vismodegib—skin cancer	0.00303	0.0102	CcSEcCtD
Nimodipine—Ileus—Docetaxel—skin cancer	0.00291	0.00979	CcSEcCtD
Nimodipine—Phlebitis—Dactinomycin—skin cancer	0.00289	0.00971	CcSEcCtD
Nimodipine—Depression—Imiquimod—skin cancer	0.00289	0.0097	CcSEcCtD
Nimodipine—CACNB1—lymph node—skin cancer	0.00285	0.0149	CbGeAlD
Nimodipine—Cardiac disorder—Vemurafenib—skin cancer	0.00283	0.00951	CcSEcCtD
Nimodipine—Angiopathy—Vemurafenib—skin cancer	0.00277	0.00929	CcSEcCtD
Nimodipine—Hepatobiliary disease—Imiquimod—skin cancer	0.00274	0.0092	CcSEcCtD
Nimodipine—CACNB3—lymph node—skin cancer	0.00274	0.0143	CbGeAlD
Nimodipine—NR3C2—mammalian vulva—skin cancer	0.0027	0.0141	CbGeAlD
Nimodipine—AHR—Integrated Breast Cancer Pathway—XRCC3—skin cancer	0.00264	0.0298	CbGpPWpGaD
Nimodipine—CACNB2—head—skin cancer	0.00263	0.0137	CbGeAlD
Nimodipine—Blood alkaline phosphatase increased—Temozolomide—skin cancer	0.00259	0.0087	CcSEcCtD
Nimodipine—CACNA1C—female reproductive system—skin cancer	0.00254	0.0132	CbGeAlD
Nimodipine—Pruritus—Vismodegib—skin cancer	0.00248	0.00833	CcSEcCtD
Nimodipine—Flushing—Imiquimod—skin cancer	0.00241	0.00811	CcSEcCtD
Nimodipine—Diarrhoea—Vismodegib—skin cancer	0.0024	0.00806	CcSEcCtD
Nimodipine—Angiopathy—Imiquimod—skin cancer	0.00236	0.00793	CcSEcCtD
Nimodipine—Immune system disorder—Imiquimod—skin cancer	0.00235	0.00789	CcSEcCtD
Nimodipine—NR3C2—female reproductive system—skin cancer	0.00231	0.012	CbGeAlD
Nimodipine—Liver function test abnormal—Dactinomycin—skin cancer	0.0023	0.00772	CcSEcCtD
Nimodipine—CACNA1D—head—skin cancer	0.0023	0.012	CbGeAlD
Nimodipine—Myalgia—Vemurafenib—skin cancer	0.00226	0.00759	CcSEcCtD
Nimodipine—Vomiting—Vismodegib—skin cancer	0.00223	0.00749	CcSEcCtD
Nimodipine—Rash—Vismodegib—skin cancer	0.00221	0.00743	CcSEcCtD
Nimodipine—Dermatitis—Vismodegib—skin cancer	0.00221	0.00742	CcSEcCtD
Nimodipine—AHR—Circadian rythm related genes—NKX2-1—skin cancer	0.00221	0.0248	CbGpPWpGaD
Nimodipine—Nervous system disorder—Vemurafenib—skin cancer	0.00212	0.00714	CcSEcCtD
Nimodipine—CACNA1C—head—skin cancer	0.00212	0.011	CbGeAlD
Nimodipine—Nausea—Vismodegib—skin cancer	0.00208	0.007	CcSEcCtD
Nimodipine—Gastrointestinal haemorrhage—Fluorouracil—skin cancer	0.00208	0.00697	CcSEcCtD
Nimodipine—Phosphatase alkaline increased—Docetaxel—skin cancer	0.00206	0.00693	CcSEcCtD
Nimodipine—AHR—lymph node—skin cancer	0.00203	0.0106	CbGeAlD
Nimodipine—Hypotension—Vemurafenib—skin cancer	0.00202	0.0068	CcSEcCtD
Nimodipine—Palpitations—Imiquimod—skin cancer	0.002	0.00672	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Temozolomide—skin cancer	0.00199	0.00667	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00197	0.00663	CcSEcCtD
Nimodipine—Fluid retention—Docetaxel—skin cancer	0.00196	0.00658	CcSEcCtD
Nimodipine—Hypertension—Imiquimod—skin cancer	0.00195	0.00657	CcSEcCtD
Nimodipine—NR3C2—head—skin cancer	0.00193	0.0101	CbGeAlD
Nimodipine—Myalgia—Imiquimod—skin cancer	0.00193	0.00647	CcSEcCtD
Nimodipine—Sweating increased—Temozolomide—skin cancer	0.0019	0.00637	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00187	0.00628	CcSEcCtD
Nimodipine—Oedema—Imiquimod—skin cancer	0.00185	0.00621	CcSEcCtD
Nimodipine—Lightheadedness—Docetaxel—skin cancer	0.00185	0.0062	CcSEcCtD
Nimodipine—CACNB2—lymph node—skin cancer	0.00184	0.00959	CbGeAlD
Nimodipine—Nervous system disorder—Imiquimod—skin cancer	0.00181	0.00609	CcSEcCtD
Nimodipine—Tachycardia—Imiquimod—skin cancer	0.0018	0.00606	CcSEcCtD
Nimodipine—Hyperhidrosis—Imiquimod—skin cancer	0.00179	0.006	CcSEcCtD
Nimodipine—Phlebitis—Docetaxel—skin cancer	0.00174	0.00584	CcSEcCtD
Nimodipine—Depression—Temozolomide—skin cancer	0.00173	0.00582	CcSEcCtD
Nimodipine—Hepatitis—Dactinomycin—skin cancer	0.00172	0.00579	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Docetaxel—skin cancer	0.00172	0.00579	CcSEcCtD
Nimodipine—Flushing—Bleomycin—skin cancer	0.00171	0.00576	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—MSH2—skin cancer	0.0017	0.0192	CbGpPWpGaD
Nimodipine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00168	0.00565	CcSEcCtD
Nimodipine—Cardiac failure congestive—Docetaxel—skin cancer	0.00165	0.00555	CcSEcCtD
Nimodipine—Dyspnoea—Imiquimod—skin cancer	0.00165	0.00553	CcSEcCtD
Nimodipine—Hepatobiliary disease—Temozolomide—skin cancer	0.00164	0.00552	CcSEcCtD
Nimodipine—CACNA1D—lymph node—skin cancer	0.00161	0.00838	CbGeAlD
Nimodipine—Flushing—Dactinomycin—skin cancer	0.0016	0.00537	CcSEcCtD
Nimodipine—Hypersensitivity—Vemurafenib—skin cancer	0.0016	0.00536	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00159	0.00536	CcSEcCtD
Nimodipine—Hepatitis—Temozolomide—skin cancer	0.00156	0.00524	CcSEcCtD
Nimodipine—Pruritus—Vemurafenib—skin cancer	0.00153	0.00515	CcSEcCtD
Nimodipine—CACNB4—Axon guidance—SCN10A—skin cancer	0.00153	0.0172	CbGpPWpGaD
Nimodipine—Hyponatraemia—Docetaxel—skin cancer	0.0015	0.00505	CcSEcCtD
Nimodipine—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.0015	0.00503	CcSEcCtD
Nimodipine—Anaemia—Bleomycin—skin cancer	0.00149	0.00499	CcSEcCtD
Nimodipine—CACNA1C—lymph node—skin cancer	0.00148	0.00774	CbGeAlD
Nimodipine—Diarrhoea—Vemurafenib—skin cancer	0.00148	0.00498	CcSEcCtD
Nimodipine—Cardiac disorder—Temozolomide—skin cancer	0.00145	0.00486	CcSEcCtD
Nimodipine—Flushing—Temozolomide—skin cancer	0.00145	0.00486	CcSEcCtD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.00144	0.0163	CbGpPWpGaD
Nimodipine—Dizziness—Vemurafenib—skin cancer	0.00143	0.00481	CcSEcCtD
Nimodipine—Angiopathy—Temozolomide—skin cancer	0.00141	0.00475	CcSEcCtD
Nimodipine—Immune system disorder—Temozolomide—skin cancer	0.00141	0.00473	CcSEcCtD
Nimodipine—Anaemia—Dactinomycin—skin cancer	0.00139	0.00466	CcSEcCtD
Nimodipine—Liver function test abnormal—Docetaxel—skin cancer	0.00138	0.00465	CcSEcCtD
Nimodipine—Vomiting—Vemurafenib—skin cancer	0.00138	0.00463	CcSEcCtD
Nimodipine—Myalgia—Bleomycin—skin cancer	0.00137	0.0046	CcSEcCtD
Nimodipine—Rash—Vemurafenib—skin cancer	0.00137	0.00459	CcSEcCtD
Nimodipine—Dermatitis—Vemurafenib—skin cancer	0.00136	0.00458	CcSEcCtD
Nimodipine—Hypersensitivity—Imiquimod—skin cancer	0.00136	0.00457	CcSEcCtD
Nimodipine—Headache—Vemurafenib—skin cancer	0.00136	0.00456	CcSEcCtD
Nimodipine—NR3C2—lymph node—skin cancer	0.00135	0.00704	CbGeAlD
Nimodipine—Cramp muscle—Docetaxel—skin cancer	0.00135	0.00453	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00132	0.00444	CcSEcCtD
Nimodipine—Oedema—Bleomycin—skin cancer	0.00131	0.00441	CcSEcCtD
Nimodipine—Pruritus—Imiquimod—skin cancer	0.00131	0.00439	CcSEcCtD
Nimodipine—Nausea—Vemurafenib—skin cancer	0.00129	0.00432	CcSEcCtD
Nimodipine—Thrombocytopenia—Bleomycin—skin cancer	0.00128	0.00432	CcSEcCtD
Nimodipine—Myalgia—Dactinomycin—skin cancer	0.00128	0.00429	CcSEcCtD
Nimodipine—Diarrhoea—Imiquimod—skin cancer	0.00126	0.00425	CcSEcCtD
Nimodipine—Anaemia—Temozolomide—skin cancer	0.00125	0.00421	CcSEcCtD
Nimodipine—Hypotension—Bleomycin—skin cancer	0.00123	0.00412	CcSEcCtD
Nimodipine—Oedema—Dactinomycin—skin cancer	0.00122	0.00411	CcSEcCtD
Nimodipine—CACNB3—Axon guidance—SCN10A—skin cancer	0.00122	0.0138	CbGpPWpGaD
Nimodipine—Dizziness—Imiquimod—skin cancer	0.00122	0.0041	CcSEcCtD
Nimodipine—Palpitations—Temozolomide—skin cancer	0.0012	0.00403	CcSEcCtD
Nimodipine—Thrombocytopenia—Dactinomycin—skin cancer	0.0012	0.00403	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.0012	0.00402	CcSEcCtD
Nimodipine—CACNB1—Axon guidance—SCN10A—skin cancer	0.00119	0.0134	CbGpPWpGaD
Nimodipine—Vomiting—Imiquimod—skin cancer	0.00117	0.00395	CcSEcCtD
Nimodipine—Hypertension—Temozolomide—skin cancer	0.00117	0.00393	CcSEcCtD
Nimodipine—Dyspnoea—Bleomycin—skin cancer	0.00117	0.00393	CcSEcCtD
Nimodipine—Rash—Imiquimod—skin cancer	0.00116	0.00391	CcSEcCtD
Nimodipine—Dermatitis—Imiquimod—skin cancer	0.00116	0.00391	CcSEcCtD
Nimodipine—Headache—Imiquimod—skin cancer	0.00116	0.00389	CcSEcCtD
Nimodipine—Anaemia—Fluorouracil—skin cancer	0.00115	0.00388	CcSEcCtD
Nimodipine—Myalgia—Temozolomide—skin cancer	0.00115	0.00388	CcSEcCtD
Nimodipine—Jaundice—Docetaxel—skin cancer	0.00113	0.00378	CcSEcCtD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—NRAS—skin cancer	0.00112	0.0126	CbGpPWpGaD
Nimodipine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00111	0.00375	CcSEcCtD
Nimodipine—Oedema—Temozolomide—skin cancer	0.00111	0.00372	CcSEcCtD
Nimodipine—Nausea—Imiquimod—skin cancer	0.0011	0.00369	CcSEcCtD
Nimodipine—CACNB4—Developmental Biology—SCN10A—skin cancer	0.00109	0.0123	CbGpPWpGaD
Nimodipine—Hepatobiliary disease—Docetaxel—skin cancer	0.00109	0.00367	CcSEcCtD
Nimodipine—Nervous system disorder—Temozolomide—skin cancer	0.00109	0.00365	CcSEcCtD
Nimodipine—Thrombocytopenia—Temozolomide—skin cancer	0.00108	0.00364	CcSEcCtD
Nimodipine—Hyperhidrosis—Temozolomide—skin cancer	0.00107	0.0036	CcSEcCtD
Nimodipine—Myalgia—Fluorouracil—skin cancer	0.00106	0.00357	CcSEcCtD
Nimodipine—Hepatitis—Docetaxel—skin cancer	0.00104	0.00348	CcSEcCtD
Nimodipine—Oedema—Fluorouracil—skin cancer	0.00102	0.00343	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00101	0.00339	CcSEcCtD
Nimodipine—Nervous system disorder—Fluorouracil—skin cancer	0.001	0.00336	CcSEcCtD
Nimodipine—Thrombocytopenia—Fluorouracil—skin cancer	0.000999	0.00336	CcSEcCtD
Nimodipine—Tachycardia—Fluorouracil—skin cancer	0.000995	0.00334	CcSEcCtD
Nimodipine—Dyspnoea—Temozolomide—skin cancer	0.000987	0.00332	CcSEcCtD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—KRAS—skin cancer	0.000967	0.0109	CbGpPWpGaD
Nimodipine—Hypersensitivity—Bleomycin—skin cancer	0.000967	0.00325	CcSEcCtD
Nimodipine—Cardiac disorder—Docetaxel—skin cancer	0.000962	0.00323	CcSEcCtD
Nimodipine—Flushing—Docetaxel—skin cancer	0.000962	0.00323	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000956	0.00321	CcSEcCtD
Nimodipine—Hypotension—Fluorouracil—skin cancer	0.000953	0.0032	CcSEcCtD
Nimodipine—Angiopathy—Docetaxel—skin cancer	0.00094	0.00316	CcSEcCtD
Nimodipine—CYP3A4—female reproductive system—skin cancer	0.000937	0.00488	CbGeAlD
Nimodipine—Immune system disorder—Docetaxel—skin cancer	0.000936	0.00314	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000929	0.00312	CcSEcCtD
Nimodipine—Pruritus—Bleomycin—skin cancer	0.000928	0.00312	CcSEcCtD
Nimodipine—Dyspnoea—Fluorouracil—skin cancer	0.000909	0.00306	CcSEcCtD
Nimodipine—Hypersensitivity—Dactinomycin—skin cancer	0.000902	0.00303	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00088	0.00296	CcSEcCtD
Nimodipine—CACNB4—Axon guidance—RASA1—skin cancer	0.000879	0.00989	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—SCN10A—skin cancer	0.000873	0.00982	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—SCN10A—skin cancer	0.000871	0.00981	CbGpPWpGaD
Nimodipine—Muscle spasms—Docetaxel—skin cancer	0.000867	0.00291	CcSEcCtD
Nimodipine—CACNB1—Developmental Biology—SCN10A—skin cancer	0.000849	0.00955	CbGpPWpGaD
Nimodipine—Diarrhoea—Dactinomycin—skin cancer	0.000837	0.00281	CcSEcCtD
Nimodipine—CACNB4—NCAM signaling for neurite out-growth—NRAS—skin cancer	0.000835	0.0094	CbGpPWpGaD
Nimodipine—Vomiting—Bleomycin—skin cancer	0.000834	0.0028	CcSEcCtD
Nimodipine—Anaemia—Docetaxel—skin cancer	0.000834	0.0028	CcSEcCtD
Nimodipine—Rash—Bleomycin—skin cancer	0.000827	0.00278	CcSEcCtD
Nimodipine—Dermatitis—Bleomycin—skin cancer	0.000827	0.00278	CcSEcCtD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—HRAS—skin cancer	0.000822	0.00925	CbGpPWpGaD
Nimodipine—Hypersensitivity—Temozolomide—skin cancer	0.000816	0.00274	CcSEcCtD
Nimodipine—CACNA1F—Alzheimers Disease—TP53—skin cancer	0.000805	0.00905	CbGpPWpGaD
Nimodipine—Palpitations—Docetaxel—skin cancer	0.000797	0.00268	CcSEcCtD
Nimodipine—Pruritus—Temozolomide—skin cancer	0.000783	0.00263	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—CDK4—skin cancer	0.000781	0.00879	CbGpPWpGaD
Nimodipine—Nausea—Bleomycin—skin cancer	0.000779	0.00262	CcSEcCtD
Nimodipine—Hypertension—Docetaxel—skin cancer	0.000779	0.00262	CcSEcCtD
Nimodipine—Vomiting—Dactinomycin—skin cancer	0.000778	0.00261	CcSEcCtD
Nimodipine—Rash—Dactinomycin—skin cancer	0.000772	0.00259	CcSEcCtD
Nimodipine—Myalgia—Docetaxel—skin cancer	0.000768	0.00258	CcSEcCtD
Nimodipine—Diarrhoea—Temozolomide—skin cancer	0.000757	0.00254	CcSEcCtD
Nimodipine—Hypersensitivity—Fluorouracil—skin cancer	0.000751	0.00252	CcSEcCtD
Nimodipine—CACNB2—Axon guidance—SCN10A—skin cancer	0.000747	0.00841	CbGpPWpGaD
Nimodipine—Oedema—Docetaxel—skin cancer	0.000736	0.00247	CcSEcCtD
Nimodipine—Dizziness—Temozolomide—skin cancer	0.000732	0.00246	CcSEcCtD
Nimodipine—Nausea—Dactinomycin—skin cancer	0.000727	0.00244	CcSEcCtD
Nimodipine—Nervous system disorder—Docetaxel—skin cancer	0.000722	0.00243	CcSEcCtD
Nimodipine—Pruritus—Fluorouracil—skin cancer	0.000722	0.00242	CcSEcCtD
Nimodipine—Thrombocytopenia—Docetaxel—skin cancer	0.000721	0.00242	CcSEcCtD
Nimodipine—CACNB4—NCAM signaling for neurite out-growth—KRAS—skin cancer	0.000719	0.00809	CbGpPWpGaD
Nimodipine—Tachycardia—Docetaxel—skin cancer	0.000718	0.00241	CcSEcCtD
Nimodipine—CACNA1D—Axon guidance—SCN10A—skin cancer	0.000708	0.00796	CbGpPWpGaD
Nimodipine—Vomiting—Temozolomide—skin cancer	0.000704	0.00236	CcSEcCtD
Nimodipine—CACNB3—Axon guidance—RASA1—skin cancer	0.000702	0.0079	CbGpPWpGaD
Nimodipine—Rash—Temozolomide—skin cancer	0.000698	0.00235	CcSEcCtD
Nimodipine—Diarrhoea—Fluorouracil—skin cancer	0.000698	0.00234	CcSEcCtD
Nimodipine—Dermatitis—Temozolomide—skin cancer	0.000697	0.00234	CcSEcCtD
Nimodipine—Headache—Temozolomide—skin cancer	0.000693	0.00233	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—BRAF—skin cancer	0.000691	0.00777	CbGpPWpGaD
Nimodipine—Hypotension—Docetaxel—skin cancer	0.000688	0.00231	CcSEcCtD
Nimodipine—CACNB1—Axon guidance—RASA1—skin cancer	0.000683	0.00769	CbGpPWpGaD
Nimodipine—Dizziness—Fluorouracil—skin cancer	0.000674	0.00227	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000671	0.00225	CcSEcCtD
Nimodipine—CACNB3—NCAM signaling for neurite out-growth—NRAS—skin cancer	0.000668	0.00752	CbGpPWpGaD
Nimodipine—Nausea—Temozolomide—skin cancer	0.000657	0.00221	CcSEcCtD
Nimodipine—Dyspnoea—Docetaxel—skin cancer	0.000656	0.00221	CcSEcCtD
Nimodipine—CACNB1—NCAM signaling for neurite out-growth—NRAS—skin cancer	0.00065	0.00731	CbGpPWpGaD
Nimodipine—Vomiting—Fluorouracil—skin cancer	0.000648	0.00218	CcSEcCtD
Nimodipine—Rash—Fluorouracil—skin cancer	0.000643	0.00216	CcSEcCtD
Nimodipine—Dermatitis—Fluorouracil—skin cancer	0.000642	0.00216	CcSEcCtD
Nimodipine—Headache—Fluorouracil—skin cancer	0.000639	0.00215	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000636	0.00214	CcSEcCtD
Nimodipine—CACNB4—Developmental Biology—RASA1—skin cancer	0.000627	0.00706	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—SCN10A—skin cancer	0.000622	0.007	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—SCN10A—skin cancer	0.000622	0.007	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—CDK4—skin cancer	0.000621	0.00699	CbGpPWpGaD
Nimodipine—CACNB4—NCAM signaling for neurite out-growth—HRAS—skin cancer	0.000611	0.00688	CbGpPWpGaD
Nimodipine—Nausea—Fluorouracil—skin cancer	0.000606	0.00204	CcSEcCtD
Nimodipine—CACNB4—NCAM signaling for neurite out-growth—IL6—skin cancer	0.000585	0.00658	CbGpPWpGaD
Nimodipine—CACNB3—NCAM signaling for neurite out-growth—KRAS—skin cancer	0.000575	0.00647	CbGpPWpGaD
Nimodipine—CACNB4—Transmission across Chemical Synapses—BRAF—skin cancer	0.000561	0.00631	CbGpPWpGaD
Nimodipine—CACNB1—NCAM signaling for neurite out-growth—KRAS—skin cancer	0.000559	0.00629	CbGpPWpGaD
Nimodipine—Hypersensitivity—Docetaxel—skin cancer	0.000542	0.00182	CcSEcCtD
Nimodipine—CACNB2—Developmental Biology—SCN10A—skin cancer	0.000533	0.006	CbGpPWpGaD
Nimodipine—Pruritus—Docetaxel—skin cancer	0.000521	0.00175	CcSEcCtD
Nimodipine—CACNA1D—Developmental Biology—SCN10A—skin cancer	0.000505	0.00568	CbGpPWpGaD
Nimodipine—Diarrhoea—Docetaxel—skin cancer	0.000504	0.00169	CcSEcCtD
Nimodipine—CACNB3—Developmental Biology—RASA1—skin cancer	0.000501	0.00564	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—RASA1—skin cancer	0.000501	0.00563	CbGpPWpGaD
Nimodipine—CACNB3—NCAM signaling for neurite out-growth—HRAS—skin cancer	0.000489	0.0055	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—RASA1—skin cancer	0.000488	0.00549	CbGpPWpGaD
Nimodipine—Dizziness—Docetaxel—skin cancer	0.000487	0.00164	CcSEcCtD
Nimodipine—CACNA1S—NCAM signaling for neurite out-growth—NRAS—skin cancer	0.000476	0.00536	CbGpPWpGaD
Nimodipine—CACNB1—NCAM signaling for neurite out-growth—HRAS—skin cancer	0.000475	0.00535	CbGpPWpGaD
Nimodipine—Vomiting—Docetaxel—skin cancer	0.000468	0.00157	CcSEcCtD
Nimodipine—CACNB3—NCAM signaling for neurite out-growth—IL6—skin cancer	0.000468	0.00526	CbGpPWpGaD
Nimodipine—Rash—Docetaxel—skin cancer	0.000464	0.00156	CcSEcCtD
Nimodipine—Dermatitis—Docetaxel—skin cancer	0.000464	0.00156	CcSEcCtD
Nimodipine—Headache—Docetaxel—skin cancer	0.000461	0.00155	CcSEcCtD
Nimodipine—CACNB1—NCAM signaling for neurite out-growth—IL6—skin cancer	0.000455	0.00512	CbGpPWpGaD
Nimodipine—CACNB3—Transmission across Chemical Synapses—BRAF—skin cancer	0.000448	0.00505	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—SCN10A—skin cancer	0.000444	0.00499	CbGpPWpGaD
Nimodipine—Nausea—Docetaxel—skin cancer	0.000437	0.00147	CcSEcCtD
Nimodipine—CACNB1—Transmission across Chemical Synapses—BRAF—skin cancer	0.000436	0.00491	CbGpPWpGaD
Nimodipine—CACNB4—Neuronal System—BRAF—skin cancer	0.00043	0.00484	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—RASA1—skin cancer	0.000429	0.00483	CbGpPWpGaD
Nimodipine—CACNA1S—NCAM signaling for neurite out-growth—KRAS—skin cancer	0.00041	0.00461	CbGpPWpGaD
Nimodipine—CACNB2—NCAM signaling for neurite out-growth—NRAS—skin cancer	0.000408	0.00459	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—RASA1—skin cancer	0.000406	0.00457	CbGpPWpGaD
Nimodipine—CACNA1D—NCAM signaling for neurite out-growth—NRAS—skin cancer	0.000386	0.00435	CbGpPWpGaD
Nimodipine—AHR—Integrated Breast Cancer Pathway—KRAS—skin cancer	0.000374	0.0042	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—PLIN2—skin cancer	0.000366	0.00412	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—RASA1—skin cancer	0.000357	0.00402	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—RASA1—skin cancer	0.000357	0.00402	CbGpPWpGaD
Nimodipine—CACNB2—NCAM signaling for neurite out-growth—KRAS—skin cancer	0.000351	0.00395	CbGpPWpGaD
Nimodipine—CACNA1S—NCAM signaling for neurite out-growth—HRAS—skin cancer	0.000348	0.00392	CbGpPWpGaD
Nimodipine—CACNB3—Neuronal System—BRAF—skin cancer	0.000344	0.00387	CbGpPWpGaD
Nimodipine—AHR—Adipogenesis—IL6—skin cancer	0.000343	0.00386	CbGpPWpGaD
Nimodipine—CACNA1C—NCAM signaling for neurite out-growth—NRAS—skin cancer	0.00034	0.00382	CbGpPWpGaD
Nimodipine—CACNB1—Neuronal System—BRAF—skin cancer	0.000334	0.00376	CbGpPWpGaD
Nimodipine—CACNA1S—NCAM signaling for neurite out-growth—IL6—skin cancer	0.000333	0.00375	CbGpPWpGaD
Nimodipine—CACNA1D—NCAM signaling for neurite out-growth—KRAS—skin cancer	0.000333	0.00374	CbGpPWpGaD
Nimodipine—AHR—Integrated Breast Cancer Pathway—TP53—skin cancer	0.000332	0.00374	CbGpPWpGaD
Nimodipine—CACNA1S—Alzheimers Disease—TP53—skin cancer	0.000323	0.00363	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—CDK4—skin cancer	0.000307	0.00346	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—RASA1—skin cancer	0.000306	0.00345	CbGpPWpGaD
Nimodipine—CACNB2—NCAM signaling for neurite out-growth—HRAS—skin cancer	0.000298	0.00336	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—CSPG4—skin cancer	0.000295	0.00332	CbGpPWpGaD
Nimodipine—CACNA1C—NCAM signaling for neurite out-growth—KRAS—skin cancer	0.000292	0.00329	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—RASA1—skin cancer	0.00029	0.00326	CbGpPWpGaD
Nimodipine—CACNB2—NCAM signaling for neurite out-growth—IL6—skin cancer	0.000286	0.00321	CbGpPWpGaD
Nimodipine—CACNA1D—NCAM signaling for neurite out-growth—HRAS—skin cancer	0.000283	0.00318	CbGpPWpGaD
Nimodipine—CACNB2—Transmission across Chemical Synapses—BRAF—skin cancer	0.000274	0.00308	CbGpPWpGaD
Nimodipine—CACNA1D—NCAM signaling for neurite out-growth—IL6—skin cancer	0.000271	0.00304	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—TP53—skin cancer	0.000264	0.00297	CbGpPWpGaD
Nimodipine—CACNA1D—Alzheimers Disease—TP53—skin cancer	0.000262	0.00295	CbGpPWpGaD
Nimodipine—CACNB4—Transmission across Chemical Synapses—HRAS—skin cancer	0.000258	0.0029	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—RASA1—skin cancer	0.000255	0.00287	CbGpPWpGaD
Nimodipine—CACNA1C—NCAM signaling for neurite out-growth—HRAS—skin cancer	0.000248	0.00279	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—CDK4—skin cancer	0.000246	0.00277	CbGpPWpGaD
Nimodipine—CACNB3—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	0.000242	0.00272	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—IL6—skin cancer	0.000242	0.00272	CbGpPWpGaD
Nimodipine—CACNB4—Axon guidance—NRAS—skin cancer	0.00024	0.0027	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—CDK4—skin cancer	0.000239	0.00269	CbGpPWpGaD
Nimodipine—CACNA1C—NCAM signaling for neurite out-growth—IL6—skin cancer	0.000238	0.00267	CbGpPWpGaD
Nimodipine—CACNA1C—Alzheimers Disease—TP53—skin cancer	0.00023	0.00259	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—PLIN2—skin cancer	0.000224	0.00252	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—PLIN2—skin cancer	0.000212	0.00238	CbGpPWpGaD
Nimodipine—CACNB2—Neuronal System—BRAF—skin cancer	0.00021	0.00236	CbGpPWpGaD
Nimodipine—CACNB4—Axon guidance—KRAS—skin cancer	0.000206	0.00232	CbGpPWpGaD
Nimodipine—CACNB3—Transmission across Chemical Synapses—HRAS—skin cancer	0.000206	0.00232	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—ENO2—skin cancer	0.000201	0.00226	CbGpPWpGaD
Nimodipine—CACNB1—Transmission across Chemical Synapses—HRAS—skin cancer	0.000201	0.00226	CbGpPWpGaD
Nimodipine—CACNB4—Neuronal System—HRAS—skin cancer	0.000198	0.00222	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—NRAS—skin cancer	0.000192	0.00216	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—NRAS—skin cancer	0.000186	0.0021	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PLIN2—skin cancer	0.000186	0.00209	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—CSPG4—skin cancer	0.00018	0.00203	CbGpPWpGaD
Nimodipine—CACNB4—Axon guidance—HRAS—skin cancer	0.000175	0.00197	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—CDK4—skin cancer	0.000175	0.00197	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—NRAS—skin cancer	0.000171	0.00192	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—CSPG4—skin cancer	0.000171	0.00192	CbGpPWpGaD
Nimodipine—CACNB4—Axon guidance—IL6—skin cancer	0.000168	0.00189	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—KRAS—skin cancer	0.000165	0.00186	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—KRAS—skin cancer	0.00016	0.0018	CbGpPWpGaD
Nimodipine—CACNB3—Neuronal System—HRAS—skin cancer	0.000158	0.00178	CbGpPWpGaD
Nimodipine—CACNB1—Neuronal System—HRAS—skin cancer	0.000154	0.00173	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—CDK4—skin cancer	0.00015	0.00169	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—CSPG4—skin cancer	0.00015	0.00169	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—KRAS—skin cancer	0.000147	0.00166	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—CDK4—skin cancer	0.000142	0.0016	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—HRAS—skin cancer	0.00014	0.00158	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—NRAS—skin cancer	0.000137	0.00154	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—NRAS—skin cancer	0.000136	0.00154	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—HRAS—skin cancer	0.000136	0.00153	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—ERCC2—skin cancer	0.000135	0.00151	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—IL6—skin cancer	0.000134	0.00151	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—NRAS—skin cancer	0.000133	0.0015	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—IL6—skin cancer	0.00013	0.00147	CbGpPWpGaD
Nimodipine—CACNB2—Transmission across Chemical Synapses—HRAS—skin cancer	0.000126	0.00142	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—HRAS—skin cancer	0.000125	0.00141	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—CDK4—skin cancer	0.000125	0.00141	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—ENO2—skin cancer	0.000123	0.00138	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—IL6—skin cancer	0.00012	0.00135	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—KRAS—skin cancer	0.000118	0.00132	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—KRAS—skin cancer	0.000117	0.00132	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—NRAS—skin cancer	0.000117	0.00132	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—ERCC2—skin cancer	0.000117	0.00131	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—ENO2—skin cancer	0.000116	0.00131	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—KRAS—skin cancer	0.000114	0.00129	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—NRAS—skin cancer	0.000111	0.00125	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—ENO2—skin cancer	0.000102	0.00115	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—KRAS—skin cancer	0.000101	0.00113	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—HRAS—skin cancer	0.0001	0.00113	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—HRAS—skin cancer	9.99e-05	0.00112	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—NRAS—skin cancer	9.74e-05	0.0011	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—NRAS—skin cancer	9.74e-05	0.0011	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—HRAS—skin cancer	9.73e-05	0.00109	CbGpPWpGaD
Nimodipine—CACNB2—Neuronal System—HRAS—skin cancer	9.65e-05	0.00109	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—IL6—skin cancer	9.57e-05	0.00108	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—IL6—skin cancer	9.56e-05	0.00108	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—KRAS—skin cancer	9.54e-05	0.00107	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—IL6—skin cancer	9.31e-05	0.00105	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—HRAS—skin cancer	8.56e-05	0.000963	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—KRAS—skin cancer	8.38e-05	0.000943	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—KRAS—skin cancer	8.38e-05	0.000943	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—NRAS—skin cancer	8.35e-05	0.00094	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PLIN2—skin cancer	8.24e-05	0.000927	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—IL6—skin cancer	8.19e-05	0.000922	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—HRAS—skin cancer	8.11e-05	0.000912	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—NRAS—skin cancer	7.91e-05	0.00089	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—IL6—skin cancer	7.76e-05	0.000873	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—KRAS—skin cancer	7.19e-05	0.000809	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—HRAS—skin cancer	7.13e-05	0.000802	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—HRAS—skin cancer	7.12e-05	0.000802	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—ERCC2—skin cancer	7.12e-05	0.000801	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—PTGS2—skin cancer	6.99e-05	0.000786	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—NRAS—skin cancer	6.95e-05	0.000782	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—IL6—skin cancer	6.82e-05	0.000767	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—IL6—skin cancer	6.82e-05	0.000767	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—KRAS—skin cancer	6.81e-05	0.000766	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—ERCC2—skin cancer	6.74e-05	0.000759	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—CSPG4—skin cancer	6.64e-05	0.000747	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—HRAS—skin cancer	6.11e-05	0.000687	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—KRAS—skin cancer	5.98e-05	0.000673	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—ERCC2—skin cancer	5.92e-05	0.000667	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—IL6—skin cancer	5.85e-05	0.000658	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—HRAS—skin cancer	5.79e-05	0.000651	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—IL6—skin cancer	5.54e-05	0.000623	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—HRAS—skin cancer	5.08e-05	0.000572	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—IL6—skin cancer	4.87e-05	0.000547	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—ENO2—skin cancer	4.51e-05	0.000508	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—PTGS2—skin cancer	4.27e-05	0.00048	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—PTGS2—skin cancer	4.04e-05	0.000455	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PLIN2—skin cancer	3.83e-05	0.000431	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PTGS2—skin cancer	3.55e-05	0.0004	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—CSPG4—skin cancer	3.09e-05	0.000347	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—ERCC2—skin cancer	2.62e-05	0.000295	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—ENO2—skin cancer	2.1e-05	0.000236	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PTGS2—skin cancer	1.57e-05	0.000177	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—ERCC2—skin cancer	1.22e-05	0.000137	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PTGS2—skin cancer	7.31e-06	8.22e-05	CbGpPWpGaD
